Literature DB >> 16549802

Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease.

Alon Monsonego1, Jaime Imitola, Sanja Petrovic, Victor Zota, Anna Nemirovsky, Rona Baron, Yair Fisher, Trevor Owens, Howard L Weiner.   

Abstract

Vaccination against amyloid beta-peptide (Abeta) has been shown to be successful in reducing Abeta burden and neurotoxicity in mouse models of Alzheimer's disease (AD). However, although Abeta immunization did not show T cell infiltrates in the brain of these mice, an Abeta vaccination trial resulted in meningoencephalitis in 6% of patients with AD. Here, we explore the characteristics and specificity of Abeta-induced, T cell-mediated encephalitis in a mouse model of the disease. We demonstrate that a strong Abeta-specific T cell response is critically dependent on the immunizing T cell epitope and that epitopes differ depending on MHC genetic background. Moreover, we show that a single immunization with the dominant T cell epitope Abeta10-24 induced transient meningoencephalitis only in amyloid precursor protein (APP)-transgenic (Tg) mice expressing limited amounts of IFN-gamma under an myelin basic protein (MBP) promoter. Furthermore, immune infiltrates were targeted primarily to sites of Abeta plaques in the brain and were associated with clearance of Abeta. Immune infiltrates were not targeted to the spinal cord, consistent with what was observed in AD patients vaccinated with Abeta. Using primary cultures of microglia, we show that IFN-gamma enhanced clearance of Abeta, microglia, and T cell motility, and microglia-T cell immunological synapse formation. Our study demonstrates that limited expression of IFN-gamma in the brain, as observed during normal brain aging, is essential to promote T cell-mediated immune infiltrates after Abeta immunization and provides a model to investigate both the beneficial and detrimental effects of Abeta-specific T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16549802      PMCID: PMC1458792          DOI: 10.1073/pnas.0506209103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines.

Authors:  E H Tran; E N Prince; T Owens
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

2.  Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1.

Authors:  Z Zhang; P Nadeau; W Song; D Donoviel; M Yuan; A Bernstein; B A Yankner
Journal:  Nat Cell Biol       Date:  2000-07       Impact factor: 28.824

3.  Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.

Authors:  F Bard; C Cannon; R Barbour; R L Burke; D Games; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; I Lieberburg; R Motter; M Nguyen; F Soriano; N Vasquez; K Weiss; B Welch; P Seubert; D Schenk; T Yednock
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

4.  Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.

Authors:  H L Weiner; C A Lemere; R Maron; E T Spooner; T J Grenfell; C Mori; S Issazadeh; W W Hancock; D J Selkoe
Journal:  Ann Neurol       Date:  2000-10       Impact factor: 10.422

5.  Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils.

Authors:  J El Khoury; S E Hickman; C A Thomas; L Cao; S C Silverstein; J D Loike
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

6.  Scavenger receptor class B type I (SR-BI) mediates adhesion of neonatal murine microglia to fibrillar beta-amyloid.

Authors:  J Husemann; J D Loike; T Kodama; S C Silverstein
Journal:  J Neuroimmunol       Date:  2001-03-01       Impact factor: 3.478

7.  IFNgamma enhances microglial reactions to hippocampal axonal degeneration.

Authors:  M B Jensen; I V Hegelund; N D Lomholt; B Finsen; T Owens
Journal:  J Neurosci       Date:  2000-05-15       Impact factor: 6.167

Review 8.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

9.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

Authors:  D Morgan; D M Diamond; P E Gottschall; K E Ugen; C Dickey; J Hardy; K Duff; P Jantzen; G DiCarlo; D Wilcock; K Connor; J Hatcher; C Hope; M Gordon; G W Arendash
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

10.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

View more
  62 in total

Review 1.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

2.  Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice.

Authors:  Masaru Yamamoto; Tomomi Kiyota; Masahide Horiba; James L Buescher; Shannon M Walsh; Howard E Gendelman; Tsuneya Ikezu
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 3.  Therapeutic strategies for Alzheimer's disease.

Authors:  Donna M Barten; Charles F Albright
Journal:  Mol Neurobiol       Date:  2008-06-26       Impact factor: 5.590

Review 4.  Immune activation in brain aging and neurodegeneration: too much or too little?

Authors:  Kurt M Lucin; Tony Wyss-Coray
Journal:  Neuron       Date:  2009-10-15       Impact factor: 17.173

5.  DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.

Authors:  Doris Lambracht-Washington; Bao-Xi Qu; Min Fu; Todd N Eagar; Olaf Stüve; Roger N Rosenberg
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272

6.  DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.

Authors:  Doris Lambracht-Washington; Bao-Xi Qu; Min Fu; Larry D Anderson; Olaf Stüve; Todd N Eagar; Roger N Rosenberg
Journal:  Cell Mol Neurobiol       Date:  2011-04-06       Impact factor: 5.046

7.  Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1.

Authors:  Marion S Buckwalter; Bronwen S Coleman; Manuel Buttini; Robin Barbour; Dale Schenk; Dora Games; Peter Seubert; Tony Wyss-Coray
Journal:  J Neurosci       Date:  2006-11-01       Impact factor: 6.167

Review 8.  CD4 T cells in immunity and immunotherapy of Alzheimer's disease.

Authors:  Alon Monsonego; Anna Nemirovsky; Idan Harpaz
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

9.  A limited role for microglia in antibody mediated plaque clearance in APP mice.

Authors:  Monica Garcia-Alloza; Brian J Ferrara; Sarah A Dodwell; Gregory A Hickey; Bradley T Hyman; Brian J Bacskai
Journal:  Neurobiol Dis       Date:  2007-07-28       Impact factor: 5.996

10.  T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease.

Authors:  Yair Fisher; Anna Nemirovsky; Rona Baron; Alon Monsonego
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.